Inhibrx to Present INBRX-101 Data at ATS 2022 Annual Meeting

SAN DIEGO, April 5, 2022 /PRNewswire/ — Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that late-breaking data from INBRX-101 will be presented at the American Thoracic Society…

Click here to view original post